Given that PROFILE was a randomized controlled trial, the effectiveness of the alternative strategies could be thoroughly assessed with minimal risk of confounding, unlike some previous health economic analyses that have sought to assess “early” use of anti-TNF therapy in Crohn’s disease using only observational data.12 This evidence concerns the gene TNF and Crohn disease.